eve
HEALTH GROUP

SMARTER INNOVATION, *BETTER DELIVERY*

ADVANCING PHARMACEUTICAL AND NUTRACEUTICAL DELIVERY FOR BETTER HEALTH OUTCOMES.

2
PRODUCTS LAUNCHED

SAS-B
COMMERCIALISATION STAGE

PARTNER-LED
LICENSING MODEL

ASX: EVE

Investment Highlights

A capital-efficient reformulation platform built for partner-led scale

Strategic Pillars

Capital-Light Model

No large internal sales force — monetise through licensing and supply partnerships after proving initial product pathway

Proprietary Reformulation Platform

Delivery technology enhancing proven pharmaceutical compounds for faster onset.

Partner-Led Distribution

Scalable deployment through established pharmaceutical marketing channels.

Proof Points

SAS-B Validation

Two products validating strategy via Australia's SAS-B pathway.

Licensing discussions and EOIs from potential distribution and commercialisation partners — establishing pre-scaling platform.

Regulatory Pathway

Targeting a Bioequivalence testing only pathway for ARTG registration to avoid phased trials.

Revenue Scaling Potential

Rapid scaling post-ARTG registration through partner deployment networks.

Bioequivalence validation provides a capital-efficient proof point for ARTG registration.

Progress To Date

Q2 2025

Nextract Acquisition

Completed the purchase of Nextract and its solubility and formulation IP for Men's and Women's Health

Pharmaceutical Company

Eve Health Group becomes a registered Pharmaceutical company

Q3 2025

First Product launched

Dyspro for women's health launched in Australian under SAS(B)

Q4 2025

Capital Raise

$1.1m capital raise completed.

Regulatory Progression

Shortlist of Bioequivalence candidates identified.

Dyspro Patient access platform launch

www.reclaimthecycle.com.au website launched. Connecting patients to telehealth partners who can prescribe Dyspro

Q1 2026

Second Product Launch

Libbo for Men's health launched in Australia under SAS(B)

Libbo Patient access platform launch

www.stiffissue.com website launched to connect potential patients to prescribers.

Capital Raise

$1.3m capital raised including $400,000 from a strategic cornerstone investor.

Ongoing

Licensing Strategy

Strategic positioning for licensing partners to deploy post-registration.

Two Products Proving the Platform

Proof-of-concept for Eve's reformulation strategy. Long-term monetisation through licensing and supply.

WOMEN'S HEALTH

Dyspro™

Fast-acting, non-hormonal treatment for menstrual pain and endometriosis.

ONSET COMPARISON

Traditional NSAIDs	45–60 min
Hormonal therapies	Ongoing
Dyspro™	**~15 min**

MEN'S HEALTH

LIBBO™

Rapid-delivery oral film formulation of vardenafil for improved speed of onset, convenience and patient experience in ED.

ONSET COMPARISON

Traditional tablets	45–60 min
Libbo™	**~15 min**

✓ Fast onset ✓ Large global market

✓ SAS-B validation underway ✓ Partner-led scale

Note: Bioavailability and performance outcomes are subject to confirmation via clinical evaluation. Provisional Patent Application No. 2024902673 outlines nanoemulsion delivery for transmucosal absorption. Preliminary user outcomes suggest favourable onset profile; clinical validation is pending.

SAS(B) Validation Model

Validation infrastructure de-risking partner deployment.

1 — Patient Education

reclaimthecycle.com
stiffissue.com

2 — Telehealth Consult

hubMed
TeleDocs Clinic

3 — SAS-B Prescription

When clinically appropriate.

4 — Pharmacy Fulfilment

Chemist2U infrastructure

5 — Home Delivery

Direct to patient

Licensing discussions and expressions of interest from potential distribution and commercialisation partners — establishing pre-scaling infrastructure ahead of full ARTG registration.

What this validates

- ✓ Patient acquisition model validated
- ✓ Telehealth prescribing workflow proven
- ✓ Pharmacy logistics execution confirmed
- ✓ Regulatory compliance processes tested

Proprietary Technology Platform

A reformulation engine built for partner-led commercialisation

API Compound

Proven active pharmaceutical ingredient.

Improved Delivery

Faster onset, higher bioavailability.

Reformulation

Proprietary solubility enhancement technology.

Partner Deployment

License or supply into established networks.

Proprietary Nano-emulsion System

- ✓ Enhanced Solubility
- ✓ Versatile
- ✓ Patent Pending
- ✓ Improved Bioavailability

Capital-Light Commercial Model

From reformulation to partner-led revenue

1

Identify High-Value API

Select proven compounds with large addressable markets.

2

Reformulate via Platform

Apply proprietary solubility and delivery technology.

3

Validate via SAS-B

Pilot commercialisation through regulatory early-access pathways.

4

Register Product

Full regulatory approval across target geographies.

5

Partner Deployment

License or supply into established distribution networks.

Capital Efficient | **Scalable** | **Repeatable**

Bioequivalence validation provides a capital-efficient proof point for ARTG registration.

Two Large, Underserved Markets

Significant unmet need in both therapeutic areas

WOMEN'S HEALTH

~80% Global dysmenorrhoea prevalence	**>40%** NSAID discontinuation rate
1 in 7 Australian women are affected by endometriosis	**USD 10.9B** Global addressable market (2024)
90% Aus women/girls with dysmenorrhoea	**USD 18.5B** Market size projection (2034)

MEN'S HEALTH

~50% Global ED prevalence (age 40+)	**50%** Patients stop purchasing PDE5Is
322m Men globally affected by ED (2025)	**USD 5.3B** Global ED market size (2025)
3m Australian men impacted by ED	**7.6%** Market CAGR 2025–2032

R&D Pipeline Underway



Future EVE Drug Reformulation Targets

Name	Sale	Expiry
Eliquis (Apixaban)	$12.2B	2026
Biktarvy (Bictegravir)	$11.9B	2033
Xarelto (Rivaroxaban)	$6.8B	2025
Xtandi (Enzalutamide)	$6.3B	2027
Farxiga **(**Dapagliflozin)	$6.0B	2025
Imbruvica (Ibrutinib)	$4.9B	2027
Total Market Value	**$48.1B**	

Source: Dr Joanna Sadowska (PhD)

Key Milestones & Catalysts

Near-term value drivers over next 12 months

Upcoming Milestones

Q2 2026	Commencement of BE Study for Libbo which is an integral requirement of ARTG registration. First Licensing and marketing partners for Libbo and Dyspro secured.
Q3 2026	Small Batch manufacture for BE Study of PE and Combo PE/ED products commences. Small Batch manufacture for BE study of Apixaban product commences.
Q4 2026	Completion of BE study for Libbo and submission to TGA of ARTG registration application BE Study for PE, Combo PD/ED and Apixaban product commences. First Licensing partners for PE and Combo PD/ED products secured.
Q1 2027	TGA decision on registration of Libbo to the ARTG expected. Completion of BE studies for PE, Combo PD/ED and Apixaban products. First licensing partners for Apixaban product secured.

Strategic Timeline to Scalable Revenue

From Pipeline to Commercialisation — translating validated reformulation candidates into licensing and supply partnerships.

1

Reformulation Engine

Continuously identify, reformulate and improve high-value pharmaceutical compounds.

2

Regulatory Advancement

Progress products from SAS-B through to full registration across target geographies.

3

Regulatory Advancement

Deploy registered products into established pharmaceutical distribution networks.

4

Demand Validation

Partner platforms demonstrate real-world demand and validate prescriber workflows.

Current · Near-Term | **0–18 months · Mid-Term** | **18-36 months · Long-Term**

Corporate Snapshot

Streamlined structure, experienced leadership

Snapshot	
ASX Ticker	EVE
Share Price (Mar 2026)	A$0.020
Shares on Issue	352m (83.33m escrowed until 12 June 2026)
Market Capitalisation (23 Sept 2025)	A$7.04m
Cash	A$1.9m
Enterprise Value	A$8.94m

Board	Role
Rodney Hannington	Non-Executive Chairman
Bill Fry	Non-Executive Director
Dr Stuart Gunzburg	Executive Director & Chief Scientific Officer

Management	Role
Damian Wood	Chief Executive Officer
Ben Rohr	Chief Operating Officer
Steven Jackson	Chief Financial Officer & Company Secretary

Patient & Societal Impact

Making a difference where it matters

Improved Access

Telehealth distribution increases treatment accessibility across underserved populations and removes barriers to care.

Faster Relief

Rapid-onset formulations dramatically improve patient experience and compliance versus slower traditional treatments.

Better Quality of Life

Addressing widespread dissatisfaction with current treatment options in both women's and men's health.

Important Notice and Disclaimer

This presentation has been prepared by and issued by Eve Health Group Limited to assist in informing interested parties about the Company and its progress. It should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company.

You should not act or refrain from acting in reliance on this presentation material. This overview does not purport to be all inclusive or to contain all information that recipients may require to make an informed assessment of the Company's prospects. You should conduct your own investigation and analysis.

This presentation contains forward-looking statements regarding the Company's intentions and future business. These statements reflect current information, expectations, intentions and strategies regarding the future and are subject to certain risks and uncertainties. Investors are cautioned not to place undue reliance on forward-looking statements.

All product-related statements reflect formulation design intent, or anecdotal user-reported outcomes from early-stage evaluations. These statements are not intended to imply proven clinical efficacy or therapeutic equivalence to existing products. Clinical trials and regulatory assessments are ongoing or pending.

Authorised for release by Stuart Gunzburg, Executive Director.

eve
HEALTH GROUP

SMARTER INNOVATION,
BETTER DELIVERY

1/245 Churchill Ave, Subiaco WA 6008
+61 8 6465 5500
e: info@evehealthgroup.com.au **w:** www.evehealthgroup.com.au